Compare ResMed Inc. (RMD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs TG Therapeutics Inc — how do they compare? ResMed Inc. trades at $197.45 (market cap $28.81B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: ResMed Inc. is far larger — about 3.5× TG Therapeutics Inc's market cap, and ResMed Inc. pays a 1.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RMD | TGTX | |
|---|---|---|
Market Cap | $28.81B | $8.26B |
Sector | Health | Health |
52-Week High | $293.73 | $59.06 |
52-Week Low | $182.82 | $26.39 |
Enterprise Value | $27.99B | $8.50B |
Dividend Yield | 1.21% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
